2193 Investigating Patient and Tumor Characteristics of Surgically Resected Meningiomas in Patients Previously on Depo Medroxyprogesterone

View at publisher Summarise with VIRAT
Authors: Alan J. Gordillo, Pranav Kumar, Tianqi Xiao, Pranay Soni, Pablo F. Recinos, Varun R. Kshettry
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Meningiomas are the most common benign brain tumor and have a female predilection. Hormonal factors impacting estrogen levels, such as high body mass index (BMI) and hormonal supplementation, have been identified as potential contributors to meningioma development and progression. Depo Medroxyprogesterone acetate (dMPA) has been investigated for its association with increased meningioma risk. However, there is little data on meningiomas characterizing this risk in the United States. METHODS: Single-center retrospective review of patients with resected meningiomas with dMPA use within a year of their initial encounter for a meningioma. Patient demographics, BMI, meningioma grade, and treatment outcomes were collected. WHO grades among those with multiple meningiomas were assessed as the highest grade of any present meningioma. RESULTS: There were twenty-one patients were identified. Median age was 40 years (IQR: 10.5), 71.4% were white, median BMI was 31.2 (IQR: 6.6), and median cumulative time on dMPA was 6 years (IQR: 11). Out of the 21 patients, 52.4% of patients had skull-base tumors, 47.6% had multiple meningiomas, and WHO grade distributions were 57.1%, 38.1%, and 4.8% for grades I/II/III, respectively. Of the twenty-one patients, 8 (38.1%) had recurrence. Patients with recurrence were more likely to be white (100% vs. 53.9%) and have multiple meningiomas (100% vs. 15.4%). Lastly, 2 patients were specifically noted to have shrinkage of tumors or improvement of symptoms after cessation of dMPA. CONCLUSIONS: This case series represents one of the first investigations of dMPA use and meningioma characteristics of a cohort from the United States. Patients within this cohort had a high rate of multiple meningiomas, skull base location, and recurrence. An investigation of tumor genetics, dMPA dosing, and inclusion of non-resected patients should be conducted to further elucidate implications of dMPA use.

Fields of Study & Subjects

Meningioma and schwannoma management Pituitary Gland Disorders and Treatments Neurosurgical Procedures and Complications

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
299–299
Publication date
26 March 2026
Language
EN